Abstracts tagged "psoriatic arthritis and risk assessment"

Abstract Number: 966 • 2018 ACR/ARHP Annual Meeting
Central Triage Clinic for Psoriatic Arthritis – Performance of Triage Methods
Lihi Eder¹, Keith Colaco², Jensen Yeung³, Chandra Farrer⁴ and Dana Jerome³, ¹Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ²Institute of Medical Science, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Women's College Hospital, Toronto, ON, Canada, ⁴Rheumatology, Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Accurate triage methods for patients with psoriasis who have musculoskeletal symptoms could lead to earlier access to rheumatology care for patients with psoriatic arthritis…
Abstract Number: 657 • 2017 ACR/ARHP Annual Meeting
Dyslipidemia Management Is Insufficient in Psoriatic Arthritis Despite Increased Cardiovascular Morbidity and Mortality
Richard Koch¹, JEAN BERNARD RUIDAVETS Sr.², Yannick Degboe³, Alain Cantagrel³, Adeline Ruyssen-Witrand⁴, JEAN FERRIERES⁵ and Arnaud Constantin³, ¹Department of Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, TOULOUSE, France, ²DEPARTMENT OF EPIDEMIOLOGY, URM 1027 INSERM, TOULOUSE UNIVERSITY HOSPITAL, TOULOUSE, France, ³Department of Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, Toulouse, France, ⁴Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, ⁵DEPARTMENT OF CARDIOLOGY, URM 1027 INSERM, TOULOUSE UNIVERSITY HOSPITAL, TOULOUSE, France
Background/Purpose: Psoriatic arthritis (PsA) is associated with increased cardiovascular (CV) morbidity and mortality. Assessing individual CV risk and achieving the recommended LDL-cholesterol (LDL-C) target could…
Abstract Number: 1714 • 2016 ACR/ARHP Annual Meeting
Risk of 10-Year Cardiovascular Disease Assessed By Framingham Risk Score Is Similar in Patients with Psoriatic Arthritis and Psoriasis As Assessed By Atherosclerotic Cardiovascular Disease and Framingham Risk Scores
Natsumi Ikumi¹, Agnes Szentpetery¹, Brian Kirby² and Oliver FitzGerald¹, ¹St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ²St. Vincent's University Hospital, Department of Dermatology, Dublin, Ireland
Background/Purpose: Patients with psoriatic arthritis (PsA) and psoriasis (PsO) are at increased risk of cardiovascular diseases (CVD) and the risk is higher in patients with…
Abstract Number: 2774 • 2016 ACR/ARHP Annual Meeting
Framingham Risk Score Discriminates Coronary Atherosclerosis in Psoriatic Arthritis Patient Better Than Other Cardiovascular Scores Do
Ho Man LAM¹, Jiayun Shen², Qing SHANG³, Tsz Ho CHENG¹, Edmund LI¹, Ka Tat WONG⁴ and Lai-Shan TAM⁵, ¹Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, China, ³Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁴Prince of Wales Hospital, Hong Kong, Hong Kong, ⁵Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
Background/Purpose: Patients with psoriatic arthritis (PsA) are associated with higher cardiovascular (CV) risks. The efficacy of established CV risk scores for predicting CV risks in…
Abstract Number: 3098 • 2016 ACR/ARHP Annual Meeting
The Occurrence of Peripheral Arthritis Mutilans in Psoriatic Arthritis Is Associated with Certain Major Histocompatibility Class I Alleles
Jon T. Giles¹, Deepak R. Jadon², Muhammad Haroon³, Jing Bi⁴, Eleanor Korendowych², William Tillett², Oliver FitzGerald⁵, Robert Winchester⁴ and Neil J. McHugh², ¹Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ⁴Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁵St. Vincent's University Hospital, Department of Rheumatology. UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
Background/Purpose: Several human leukocyte antigen (HLA) Class I loci encoding the major histocompatibility complex (MHC) have been implicated both in psoriatic arthritis (PsA) susceptibility and…
Abstract Number: 3162 • 2016 ACR/ARHP Annual Meeting
Symmetric and Asymmetric Sacroiliitis Are Associated with Different Major Histocompatibility Class I Alleles in Psoriatic Arthritis
Jon T. Giles¹, Muhammad Haroon², Deepak R. Jadon³, Raj Sengupta⁴, Alison L Nightingale⁵, Eleanor Korendowych³, Jing Bi⁶, Neil J. McHugh³, Oliver FitzGerald⁷ and Robert Winchester⁶, ¹Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²Rheumatology, Kerry General Hospital, Co Kerry, Ireland, ³Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁴Rheumatology, Royal National Hospital for Rheumatic Diseases,, Bath, United Kingdom, ⁵Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ⁶Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁷St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland
Background/Purpose: HLA-B27 has been linked to sacroiliitis (SII) in psoriatic arthritis (PsA); however, the contribution to SII of other human leukocyte antigen (HLA) Class I…
Abstract Number: 352 • 2015 ACR/ARHP Annual Meeting
Low Bone Density Is Associated with Atherosclerotic Disease in Patients with Psoriatic Arthritis
Eirik Ikdahl^1,2, Hege Kilander Høiberg³, Silvia Rollefstad², Andreas P Diamantopoulos^4,5, Grunde Wibetoe², Arthur Kavanaugh⁶, Inge C Olsen⁷, Tore K. Kvien⁷, Anne Grete Semb⁸ and Glenn Haugeberg⁹, ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁴Rheumatology, Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, ⁵Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ⁶University of California San Diego, La Jolla, CA, ⁷Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Diakonhjemmet Hospital, Oslo, Norway, ⁹Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: There is an evidence vacuum concerning the mechanisms underlying the high atherosclerotic cardiovascular disease (ASCVD) burden in patients with psoriatic arthritis (PsA). In the…
Abstract Number: 542 • 2014 ACR/ARHP Annual Meeting
Predictors for Cardiovascular Events in Patients with Psoriatic Arthritis – a Cohort Study
Lihi Eder¹, Arane Thavaneswaran¹, Vinod Chandran¹, Hua Shen², Richard J. Cook² and Dafna D. Gladman¹, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose The prevalence of cardiovascular (CV) morbidity is increased in patients with psoriatic arthritis (PsA). CV risk is only partially explained by traditional CV risk…
Abstract Number: 334 • 2013 ACR/ARHP Annual Meeting
The Joint Effect Of Carotid Ultrasound and Preventive Cardiology Referral On Cardiovascular Risk Factor Modification in Psoriatic Arthritis Patients
Michael Lucke¹, Soo Hyun Kim² and M. Elaine Husni³, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ³Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Cardiovascular disease risk is elevated in psoriatic arthritis (PsA) compared to the general population. Prior studies have demonstrated suboptimal evaluation and control of modifiable…
Abstract Number: 998 • 2012 ACR/ARHP Annual Meeting
Association Study of Genetic Risk Variants for Psoriasis in a Large Cohort of Psoriatic Arthritis, Psoriasis and Controls of the Spanish Population and Association with Relevant Clinical Subphenotypes
J. D. Cañete¹, Jose Luis Fernandez-Sueiro², Raimon Sanmarti³, Jesus Rodriguez⁴, Jordi Gratacós⁵, Rubén Queiro⁶, Juan Carlos Torre-Alonso⁷, Jose Perez Venegas⁸, Santiago Muñoz-Fernandez⁹, Carlos Gonzalez¹⁰, Carlos Montilla¹¹, Daniel Roig¹², Alba Erra¹³, Isabel Acosta¹⁴, Antonio Fernández-Nebro¹⁵, Pedro Zarco¹⁶, Arnald Alonso¹⁷, María América López-Lasanta¹⁷, Antonio Julià¹⁷, Raül Tortosa¹⁷ and Sara Marsal¹⁸, ¹Unitat d'Artritis, Servei de Reumatologia, Hospital Clínic de Barcelona,, Barcelona, Spain, ²Rheumatology Service, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, ³Rheumatology Service, Hospital Clínic of Barcelona, Barcelona, Spain, ⁴Rheumatology, Hospital Universitari de Bellvitge, Barcelona, Spain, ⁵Rheumatology Service, Hospital Parc Taulí, Sabadell (Barcelona), ⁶Rheumatology Service, Hospital Universitario Central de Asturias, Oviedo, Spain, ⁷Rheumatology Service, Hospital Monte Naranco, Oviedo, Spain, ⁸Rheumatology Service, Hospital del SAS de Jerez de la Frontera, Jerez De La Frontera, Spain, ⁹Rheumatology Service, Hospital Infanta Sofía, Madrid, Spain, ¹⁰Rheumatology Service, Hospital Gregorio Marañon, Madrid, Spain, ¹¹Unit Rheumatology, Hospital Universitario de Salamanca, Salamanca, Spain, ¹²Rheumatology Service, Hospital Universitari de Bellvitge, Hospitalet de Llobregat- Barcelona, Spain, ¹³Rheumatology Service, Hospital San Rafael, Barcelona, Spain, ¹⁴Rheumatology Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain, ¹⁵Rheumatology Service, Hospital Regional Universitario Carlos Haya, Málaga, Spain, ¹⁶Rheumatology Service, Fundación Hospital Alcorcon, Alcorcon, Madrid, Spain, ¹⁷Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ¹⁸Rheumatology, University Hospital Vall d'Hebron, Barcelona, Spain
Background/Purpose: Psoriatic Arthritis (PsA) is a complex disease with a substantial genetic risk component (first-degree relative risk ~ 55). Recently, Genomewide Association Studies (GWAS) have…
Abstract Number: 999 • 2012 ACR/ARHP Annual Meeting
Identification of New Epistatic Interactions with the HLA Region in the Genetic Etiology of Psoriasis and Psoriatic Arthritis
Sara Marsal¹, Juan D. Cañete², Jose Luis Fernandez-Sueiro³, Raimon Sanmarti², Jesus Rodriguez Moreno⁴, Jordi Gratacós⁵, Rubén Queiro⁶, Carlos Montilla⁷, Juan Carlos Torre-Alonso⁸, Jose Perez Venegas⁹, Santiago Muñoz-Fernández¹⁰, Carlos M. Gonzalez¹¹, Daniel Roig¹², Alba Erra¹³, Isabel Acosta¹, Antonio Fernández-Nebro¹⁴, Pedro Zarco¹⁵, Arnald Alonso¹⁶, María América López-Lasanta¹⁶, Raül Tortosa¹⁶ and Antonio Julià¹⁶, ¹Rheumatology Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain, ²Rheumatology Service, Hospital Clínic of Barcelona, Barcelona, Spain, ³Rheumatology Service, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, ⁴Rheumatology Service, Hospital Universitario de Bellvitge., Barcelona, Spain, ⁵Rheumatology Service, Hospital Universitari Parc Taulí, Sabadell (Barcelona), Spain, ⁶Rheumatology Service, Hospital Universitario Central de Asturias, Oviedo, Spain, ⁷Rheumatology Service, Hospital Universitario de Salamanca, Salamanca, Spain, ⁸H. Monte Naranco, Oviedo, Spain, ⁹Rheumatology Service, Hospital del SAS de Jerez de la Frontera, Jerez De La Frontera, Spain, ¹⁰Unit Rheumatology, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes (Madrid), Spain, ¹¹Rheumatology, Hospital Gregorio Maranon, Madrid, Spain, ¹²Rheumatology Service, Hospital Universitari de Bellvitge, Hospitalet de Llobregat- Barcelona, Spain, ¹³Rheumatology Service, Hospital San Rafael, Barcelona, Spain, ¹⁴Rheumatology Service, Hospital Regional Universitario Carlos Haya, Málaga, Spain, ¹⁵Rheumatology Service, Fundación Hospital Alcorcon, Alcorcon, Madrid, Spain, ¹⁶Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain
Background/Purpose: Psoriatic Arthritis (PsA) is a complex disease and is present in ~11% in patients with Psoriasis (Ps). Recently, Genomewide Association Studies (GWAS) have expanded…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].